SecBot SecBot
SECBOTREPLAY Home › Report › REPL

REPL · Replimune Group is conducting a $150 million underwritten public…

Replimune Group, Inc. · 424B5 filed Aug 10, 2026 at 07:39 ET

At the news

BEARISHIMPACT 7/10

424B5 filed Aug 10, 2026 at 07:39 ET

Replimune Group is conducting a $150 million underwritten public offering of 9,701,490 shares of common stock and pre-funded warrants to purchase 2,736,340 shares, priced at $12.06 per share, at-the-market. Net proceeds of ~$140.5 million will fund the commercial launch of TUDRIQEV (RP1), recently granted accelerated FDA approval, and continued development of the RPx platform. The offering was taken down from a shelf registration filed 17 days ago that had flagged a 30% overhang from Baker Brothers affiliates' resale registration and a going-concern warning with cash runway only through Q1 2027. This dilutive capital raise adds near-term downside, extending the runway but at the cost of ~13% dilution to existing shareholders, while the company has never generated product revenue and faces ongoing confirmatory trial requirements for TUDRIQEV's accelerated approval.

  • Offering of 9,701,490 shares of common stock at $12.06 per share and pre-funded warrants to purchase 2,736,340 shares at $12.0599 each
  • Total offering size: $149,999,956; net proceeds to company: ~$140.5 million
  • Pro forma shares outstanding post-offering: 92,418,413 (excluding new pre-funded warrant shares of 2,736,340)
  • Immediate dilution of $9.18 per share to new investors (76% dilution from offering price to as-adjusted net tangible book value of $2.88)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access